{"entity":{"id":"furlong","kind":"trial","name":"FURLONG","aka":[],"tldr":"The head-to-head trial in which furmonertinib nearly doubled the time before lung cancer grew compared with gefitinib, mirroring FLAURA with a Chinese drug.","summary":"358 patients, double blind. Median progression-free survival 20.8 versus 11.1 months (hazard ratio 0.44), with strong central nervous system activity and a tolerable safety profile. NMPA first-line approval June 2022. With AENEAS it gave China two domestic third-generation EGFR inhibitors competing with osimertinib on price after NRDL listing.","status":"positive","asOf":"2026-09-10","links":[{"label":"ClinicalTrials.gov NCT03787992","url":"https://clinicaltrials.gov/study/NCT03787992"},{"label":"Lancet Respir Med 2022","url":"https://doi.org/10.1016/S2213-2600(22)00168-0"}],"tags":["china"],"related":["flaura2","aeneas"],"cancers":["nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["egfr"],"drugs":["furmonertinib","gefitinib"],"companies":["allist"],"institutions":["shanghai-chest-hospital"],"pathways":[],"terms":[],"trials":[],"people":["lu-shun"],"bottlenecks":[],"keyPapers":["paper-furlong-lancet-respir-med-2022"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03787992","phase":"3","setting":"First-line EGFR-mutant (exon 19 deletion or L858R) locally advanced or metastatic NSCLC, China: furmonertinib vs gefitinib","sponsor":"Shanghai Allist Pharmaceuticals","result":"PFS 20.8 vs 11.1 months, HR 0.44.","started":"2019-05-30","startedType":"actual","yearReported":2022,"enrolled":358,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Furmonertinib","n":178,"value":20.8},{"name":"Gefitinib","n":180,"value":11.1}],"hr":0.44,"source":"https://doi.org/10.1016/S2213-2600(22)00168-0"}]},"route":"/trials/furlong/","neighbours":{"trial":[{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/"},{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}],"institution":[{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/"}],"person":[{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/"}],"paper":[{"id":"paper-furlong-lancet-respir-med-2022","kind":"paper","name":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","route":"/key-papers/paper-furlong-lancet-respir-med-2022/"}]}}